Scientists Discover Breakthrough Solution to Combat Drug-Resistant Gonorrhea
A new antibiotic called zoliflodacin has been found to be as effective as the current standard of care in treating gonorrhea infections, according to a large clinical trial. With gonorrhea becoming increasingly drug-resistant, zoliflodacin offers hope for a solution. The drug, taken as a single dose, has not yet been approved for use in any country. Developed by the nonprofit Global Antibiotic Research & Development Partnership (G.A.R.D.P.) in collaboration with Innoviva Specialty Therapeutics, zoliflodacin represents a new model for antibiotic development. The agreement ensures that the antibiotic will be accessible and affordable in low- and middle-income countries. While the drug may not cure all cases, it provides a pathway to address common infections, particularly in women. The next step is to prevent resistance by managing the drug's distribution and use exclusively for treating gonorrhea.
